Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Briacell Therapeutics Corp T.BCT

Alternate Symbol(s):  BCTX | BCTXW

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.


TSX:BCT - Post by User

Bullboard Posts
Post by coffintraderon Aug 12, 2011 9:20am
171 Views
Post# 18934721

ACP to conduct sampling on Dal

ACP to conduct sampling on Dal

Ansell to conduct sampling program on Dal on Aug. 13

2011-08-12 09:16 ET - News Release

Mr. Jevin Werbes reports

ANSELL CAPITAL CORP. TO COMMENCE WORK ON THE DAL PROJECT, YUKON

GroundTruth Exploration Inc. will be conducting an extensive soil samplingprogram totalling 1,400 samples onAnsell Capital Corp.'s Dal property starting in or around Aug. 13, 2011.The current soil program will follow up on historical grab samplestaken from outcrops on the property. Ridge and spur samples will becollected at 50-metre station and 100-metre line spacing. (Foradditional information, a soil sample map is posted on the company'swebsite.)

Dal property, Yukon

The property consists of 178 mineral claims covering an area ofapproximately 3,600 hectares located within an east-west corridor thathosts Atac Resources Ltd.'s Rau trend (Tiger zone) to the west andAtac's Nadaleen trend (Osiris zone) to the east. The claims arecontiguous to Atac's property within the Nadaleen trend.

Historical grab samples taken from outcrops on the property have yieldedhigh-grade gold and copper values. Two samples taken from a showing inthe east of the property assayed 20.37 grams per tonne gold, 10.4 percent copper and 8.3 g/t Au, 16.0 per cent Cu respectively. One sampletaken from a showing to the west of the property assayed 5.27 per centCu.

Chris M. Healey, PGeo, a director of Ansell, is the qualified person responsible for the technical information in this release.

Bullboard Posts